(secondQuint)A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis.

 This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a Psoriasis Area and Severity Index (PASI) score of at least 10 and an Investigator's Global Assessment (IGA) of 3 (0-4 scale).

 Following run-in subjects received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

 Subjects attended the clinic at Baseline (Day 0) when they were reviewed and confirmed they met inclusion/exclusion criteria.

 Subjects were then randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

.

 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis@highlight

This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10.

 Following run-in, subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

